ArticleScientific reports2023

Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction.

Elizabeth England et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.